FibroGen, Inc.
FGEN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $30 | $47 | $141 | $235 |
| % Growth | -36.7% | -66.7% | -40.2% | – |
| Cost of Goods Sold | $16 | $4 | $20 | $449 |
| Gross Profit | $14 | $43 | $120 | -$214 |
| % Margin | 47.5% | 91.5% | 85.6% | -90.9% |
| R&D Expenses | $96 | $266 | $297 | $387 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $49 | $86 | $125 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $19 | $13 | $0 | -$312 |
| Operating Expenses | $164 | $366 | $421 | $75 |
| Operating Income | -$150 | -$323 | -$301 | -$289 |
| % Margin | -507.8% | -689.5% | -213.9% | -122.6% |
| Other Income/Exp. Net | -$3 | -$1 | $8 | -$1 |
| Pre-Tax Income | -$153 | -$323 | -$293 | -$290 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$48 | -$284 | -$294 | -$290 |
| % Margin | -160.6% | -607.3% | -208.7% | -123.3% |
| EPS | -0.48 | -2.92 | -3.15 | -3.15 |
| % Growth | 83.6% | 7.3% | 0% | – |
| EPS Diluted | -0.48 | -2.92 | -3.15 | -3.15 |
| Weighted Avg Shares Out | 100 | 97 | 94 | 92 |
| Weighted Avg Shares Out Dil | 100 | 97 | 94 | 92 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $8 | $8 | – |
| Interest Expense | $8 | $8 | $1 | $1 |
| Depreciation & Amortization | $3 | $10 | $11 | $15 |
| EBITDA | -$142 | -$305 | -$283 | -$334 |
| % Margin | -480.8% | -652.1% | -201% | -141.8% |